Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this cross-sectional study, patients with PD (n = 64, 48 male and 16 female, mean age 69.2 ± 6.7 years, Hoehn & Yahr stage 2.7 ± 0.5, Montreal Cognitive Assessment score 25.3 ± 3.0) underwent [<sup>11</sup>C]Pittsburgh compound B β-amyloid, [<sup>11</sup>C]dihydrotetrabenazine vesicular monoamine transporter type 2 (VMAT2), and [<sup>11</sup>C]methyl 4 piperidinyl propionate acetylcholinesterase brain PET imaging and clinical assessments, including the Marin Apathy Evaluation Scale, Clinician Version.
|
31732566 |
2020 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, this study set out to characterize the relationship between VMAT2 distribution in the striatum in relation to the NMS in PD.
|
31205154 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway.
|
30471418 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study investigated whether there exist distinctive patterns of presynaptic monoamine transporter densities in the basal ganglia depending on the degree of depression in patients with PD.
|
31377233 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present results support further investigation of the role of VMAT2, and associated changes in neural circuitry in the improvement of motor and non-motor symptoms with STN DBS in PD.
|
31053531 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We apply the method to [<sup>11</sup>C]-DTBZ (VMAT2 marker) and [<sup>11</sup>C]-MP (DAT marker) data from 15 early Parkinson's disease (PD) subjects; the behavior of these two tracers/targets is well characterized providing robust reference information for the method's outcome.
|
31091502 |
2019 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
135 patients with Parkinson's Disease (PD) completed vesicular monoamine transporter type2 (VMAT2) and acetylcholinesterase PET scanning to assess the integrity of nigrostriatal dopaminergic, thalamic cholinergic, and cortical cholinergic pathways, and a behavioral test (Stroop + task-switching) that puts high demands on conflict processing, an important aspect of executive control.
|
29337277 |
2019 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
[<sup>18</sup>F]9-fluoropropyl-(+)-dihydrotetrabenazine (<sup>18</sup>F-(+)DTBZ) is a recently developed PET tracer to investigate the vesicular monoamine transporter type 2 (VMAT2) activity in measuring dopaminergic degeneration in vivo and monitoring the severity of Parkinson's disease (PD).
|
30375444 |
2018 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In vivo imaging of the striatal vesicular monoamine transporter type 2 (VMAT2) distribution using 18F-FP-(+)-DTBZ animal PET is a useful method to evaluate the efficacy of therapeutic drugs i.e., magnolol, for the management of PD.
|
28257461 |
2017 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
To circumvent this limitation, we created VMAT2-KO mice specific to the dopamine (DA) nigrostriatal pathway to analyze VMAT2's involvement in DA depletion-induced motor features associated to PD and examine the relevance of DA toxicity in the pathogenesis of neurodegeneration.
|
28963508 |
2017 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The aromatic L-amino-acid decarboxylase (AADC) defect appears to be consistently smaller than the dopamine transporter and vesicular monoamine transporter 2 defects, suggesting upregulation of AADC function in PD.
|
29165839 |
2017 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent studies found that two polymorphisms (rs363371 and rs363324) in VMAT2 might be a risk factor for Parkinson's disease (PD) in Caucasians, while the two other variants (rs1990622 and rs3173615) in TMEM106B increased the risk for frontotemporal dementia (FTD).
|
28477711 |
2017 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Based on human genetic association and meta-analysis, we first confirm the human VMAT2 (hVMAT2 or SLC18A2) promoter as a risk factor for PD in both family and unrelated US white people: marker rs363324 at -11.5 kb in the hVMAT2 promoter is reproducibly associated with PD in a cohort of nuclear families (p = 0.04506 in early-onset PD) and 3 unrelated US white people (meta-analysis p = 0.01879).
|
27137201 |
2016 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
40 % of the prioritized genes were previously associated with PD including well-known PD related genes such as SLC18A2, TH or DRD2.
|
26961748 |
2016 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human studies demonstrate that the vesicular monoamine transporter 2 (VMAT2; SLC18A2) is dysfunctional in PD brain.
|
25220836 |
2014 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We validated these indices in transgenic mice with very low vesicular uptake VMAT2-Lo) or with knockouts of the genes encoding ALDH1A1 and ALDH2 (ALDH1A1,2 KO), applied these indices in PD putamen, and estimated the percent decreases in vesicular uptake and ALDH activity in PD.
|
23786406 |
2013 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study adds to the previous evidence suggesting that variability in VMAT2 promoter region may confer a reduced risk of developing PD, presumably via mechanisms of gene overexpression.
|
23369548 |
2013 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
RGD |
Protective effect of Zhen-Wu-Tang (ZWT) through keeping DA stable and VMAT 2/DAT mRNA in balance in rats with striatal lesions induced by MPTP.
|
21291984 |
2011 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.
|
20665056 |
2010 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bakuchiol analogs, especially Delta3,2-hydroxybakuchiol, are monoamine transporter inhibitors involved in regulating dopaminergic and noradrenergic neurotransmission and may have represented potential pharmacotherapies for disorders such as Parkinson's disease, depression, and cocaine addiction.
|
18329002 |
2008 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
In addition, the altered dopamine homeostasis resulting from reduced VMAT2 function may be conducive to pathogenic mechanisms induced by genetic or environmental factors thought to be involved in Parkinson's disease.
|
17652604 |
2007 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
This finding is consistent with the prediction that increased sequestration of dopamine in secretory vesicles by VMAT2 is protective for PD.
|
16339215 |
2006 |
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
RGD |
Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
|
16269145 |
2006 |
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
This finding is consistent with the prediction that increased sequestration of dopamine in secretory vesicles by VMAT2 is protective for PD.
|
16339215 |
2006 |
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
|
16386370 |
2006 |